In silico proof of principle of machine learning-based antibody design at unconstrained scale

Author:

Akbar RahmadORCID,Robert Philippe A.ORCID,Weber Cédric R.ORCID,Widrich MichaelORCID,Frank RobertORCID,Pavlović MilenaORCID,Scheffer LonnekeORCID,Chernigovskaya MariaORCID,Snapkov IgorORCID,Slabodkin AndreiORCID,Mehta Brij BhushanORCID,Miho EnkelejdaORCID,Lund-Johansen FridtjofORCID,Andersen Jan TerjeORCID,Hochreiter SeppORCID,Haff Ingrid Hobæk,Klambauer GünterORCID,Sandve Geir KjetilORCID,Greiff VictorORCID

Abstract

AbstractGenerative machine learning (ML) has been postulated to be a major driver in the computational design of antigen-specific monoclonal antibodies (mAb). However, efforts to confirm this hypothesis have been hindered by the infeasibility of testing arbitrarily large numbers of antibody sequences for their most critical design parameters: paratope, epitope, affinity, and developability. To address this challenge, we leveraged a lattice-based antibody-antigen binding simulation framework, which incorporates a wide range of physiological antibody binding parameters. The simulation framework enables both the computation of antibody-antigen 3D-structures as well as functions as an oracle for unrestricted prospective evaluation of the antigen specificity of ML-generated antibody sequences. We found that a deep generative model, trained exclusively on antibody sequence (1D) data can be used to design native-like conformational (3D) epitope-specific antibodies, matching or exceeding the training dataset in affinity and developability variety. Furthermore, we show that transfer learning enables the generation of high-affinity antibody sequences from low-N training data. Finally, we validated that the antibody design insight gained from simulated antibody-antigen binding data is applicable to experimental real-world data. Our work establishes a priori feasibility and the theoretical foundation of high-throughput ML-based mAb design.HighlightsA large-scale dataset of 70M [3 orders of magnitude larger than the current state of the art] synthetic antibody-antigen complexes, that reflect biological complexity, allows the prospective evaluation of antibody generative deep learningCombination of generative learning, synthetic antibody-antigen binding data, and prospective evaluation shows that deep learning driven antibody design and discovery at an unconstrained level is feasibleTransfer learning (low-N learning) coupled to generative learning shows that antibody-binding rules may be transferred across unrelated antibody-antigen complexesExperimental validation of antibody-design conclusions drawn from deep learning on synthetic antibody-antigen binding dataGraphical abstractWe leverage large synthetic ground-truth data to demonstrate the (A,B) unconstrained deep generative learning-based generation of native-like antibody sequences, (C) the prospective evaluation of conformational (3D) affinity, paratope-epitope pairs, and developability. (D) Finally, we show increased generation quality of low-N-based machine learning models via transfer learning.

Publisher

Cold Spring Harbor Laboratory

Reference70 articles.

1. Development of therapeutic antibodies for the treatment of diseases

2. A human monoclonal antibody blocking SARS-CoV-2 infection

3. The growth and potential of human antiviral monoclonal antibody therapeutics

4. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases;ACS Cent Sci,2020

5. I. Torjesen , Drug development: the journey of a medicine from lab to shelf. Pharm. J. (2015) (available at https://www.pharmaceutical-journal.com/publications/tomorrows-pharmacist/drug-development-the-journey-of-a-medicine-from-lab-to-shelf/20068196.article?firstPass=false).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3